Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MM016
- Development stage
- Preclinical
- Lead developer
- Mucommune
- Modality
- Cell Therapies, Gene Therapies
01
Overview
MM016 is an investigational therapeutic candidate being developed by Mucommune. It utilizes an *in vivo* cell engineering modality, which involves the genetic or functional modification of cells directly within the patient's body. This approach aims to achieve therapeutic outcomes without the need for the complex *ex vivo* processing associated with traditional cell therapies. As of early 2024, MM016 is in the discovery phase of development. While the specific biological targets and primary disease indications remain undisclosed by the company, the program represents a novel approach to cellular reprogramming for therapeutic benefit.
Beyond the preview
Go deeper on MM016.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MM016.